Email updates

Keep up to date with the latest news and content from BMC Proceedings and BioMed Central.

This article is part of the supplement: Abstracts of the 16th International Charles Heidelberger Symposium on Cancer Research

Open Access Oral presentation

Targeting secreted heat shock protein-90alpha (Hsp90α) to prevent breast cancer progression

Zhengwei Zhao, Chieh-Fang Cheng, Rosie Kim, Mei Chen, David T Woodley and Wei Li*

Author Affiliations

Department of Dermatology and the USC-Norris Comprehensive Cancer Center, The University of Southern California Keck School of Medicine, Los Angeles, CA, USA

For all author emails, please log on.

BMC Proceedings 2010, 4(Suppl 2):O14  doi:10.1186/1753-6561-4-S2-O14

The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1753-6561/4/S2/O14


Published:24 September 2010

© 2010 Li et al; licensee BioMed Central Ltd.

Oral presentation

Heat shock protein 90 (Hsp90) has been historically known as an abundant and intracellular ATP-driven chaperone with more than 100 target proteins that often play critical roles in various branches of the signaling networks for control of cell metabolism, survival, growth and differentiation. In many cancers, Hsp90 is either over-expressed or over-activated and it, therefore, becomes a target for anti-cancer drugs with a hope to simultaneously shut down multiple constitutively activated oncogene products in cancer cells. Despite of the high expectations, the toxicity of geldanamycin (GM)-derived inhibitors in humans has been a long-standing hurdle. However, studies of past few years have demonstrated a surprising need for cancer cells to secrete Hsp90α for tissue invasion and metastasis. I will present here new evidence that the metastatic breast cancer cells, MDA-MB-231, constitutively secrete Hsp90α due to their constitutive expression of the hypoxia-inducible factor-1alpha (HIF1α). Down-regulation of either HIF1α or HIF1β completely blocked Hsp90α secretion. The main function of the secreted Hsp90α is to promote breast cancer cell motility via binding to the cell surface lipoprotein receptor LRP1 (LDL Receptor-Related Protein-1). We have mapped this important extracellular Hsp90α function to a 27-amino acid peptide located at the boundary between the linker region (LR) and the middle domain (M) of Hsp90α. Selective inhibition of the extracellular action of Hsp90 or down-regulation of LRP-1 receptor blocked breast cancer invasion in an in vitro matrigel assay and tumor formation in nude mice. Most intriguingly, since secretion of Hsp90α was only found to occur under pathological conditions such as cancer and is not part of normal cells’ life, anti-cancer drugs targeting the 27-amino acid peptide of the extracellular Hsp90α should be more effective and less toxic in humans. We propose that the novel “secreted Hsp90-LRP1 Receptor” autocrine signaling plays a role in breast cancer progression and the extracellular, not intracellular, Hsp90α is an effective and safer target for anti-cancer therapies.